Biocon Brazil Pertuzumab PDP Deal
Analysis based on 6 articles · First reported Sep 08, 2026 · Last updated Sep 08, 2026
Biocon, an Indian biopharmaceutical company, signed a partnership agreement with Bahiafarma, a public pharmaceutical laboratory of the State of Bahia, and Bionovis, a Brazilian biotechnology company, to manufacture and commercialize Pertuzumab, a monoclonal antibody for HER2-positive breast cancer, in Brazil. The consortium received a 100% allocation under Brazil's 10-year Productive Development Partnership (PDP) program, granting exclusive access to Brazil's public healthcare market, which accounts for approximately 70% of the country's demand for Pertuzumab. Biocon will receive milestone payments and a share of revenues over the 10-year period, with phased localization of production in Brazil planned. The agreement aims to expand access to the therapy and support local manufacturing capabilities.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard